48,193 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 48,193 shares of the biotechnology company's stock, valued at approximately $1,640,000. XTX Topco Ltd owned about 0.06% of Veracyte as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Blue Trust Inc. raised its stake in shares of Veracyte by 2,331.6% during the 2nd quarter. Blue Trust Inc. now owns 1,386 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 1,329 shares in the last quarter. CWM LLC raised its stake in shares of Veracyte by 168.3% during the 2nd quarter. CWM LLC now owns 1,516 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 951 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Veracyte during the 2nd quarter worth approximately $58,000. Signature Resources Capital Management LLC bought a new stake in shares of Veracyte during the 2nd quarter worth approximately $83,000. Finally, nVerses Capital LLC bought a new stake in Veracyte in the 2nd quarter valued at $85,000.

Analysts Set New Price Targets

VCYT has been the topic of several recent research reports. Needham & Company LLC increased their price objective on Veracyte from $37.00 to $44.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Scotiabank raised their price objective on Veracyte from $40.00 to $44.00 and gave the company a "sector outperform" rating in a research note on Friday, November 8th. Morgan Stanley raised their price objective on Veracyte from $26.00 to $28.00 and gave the company an "underweight" rating in a research note on Monday, November 18th. UBS Group raised their price objective on Veracyte from $43.00 to $46.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $37.00 price target (down from $38.00) on shares of Veracyte in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.13.

Insiders Place Their Bets

In other news, insider John Leite sold 1,050 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $43.25, for a total value of $45,412.50. Following the completion of the transaction, the insider now owns 73,810 shares of the company's stock, valued at approximately $3,192,282.50. This represents a 1.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Evan/ Fa Jones sold 5,173 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $35.23, for a total value of $182,244.79. Following the completion of the transaction, the director now directly owns 34,343 shares of the company's stock, valued at $1,209,903.89. This represents a 13.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,211 shares of company stock worth $787,542 in the last ninety days. 1.30% of the stock is currently owned by insiders.

Veracyte Stock Performance

Shares of VCYT traded up $1.29 during mid-day trading on Friday, reaching $44.13. 1,076,603 shares of the company were exchanged, compared to its average volume of 818,616. Veracyte, Inc. has a 52 week low of $18.61 and a 52 week high of $46.00. The stock has a market capitalization of $3.42 billion, a PE ratio of -294.20 and a beta of 1.69. The business has a 50 day simple moving average of $36.71 and a two-hundred day simple moving average of $29.82.

Veracyte (NASDAQ:VCYT - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.16. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The company had revenue of $115.86 million for the quarter, compared to analyst estimates of $109.81 million. During the same period in the previous year, the company posted ($0.03) EPS. The firm's revenue for the quarter was up 28.6% compared to the same quarter last year. On average, analysts predict that Veracyte, Inc. will post 0.38 EPS for the current year.

Veracyte Company Profile

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.